Ovid therapeutics Inc (OVID)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.58-5.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · OVID
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.5% |
| Our one-year growth estimate | diamond | -74.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 44.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
OVID — CFO transition
Dated 2026-07-08
Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary — Jeffrey Rona: Mr. Rona mutually agreed to transition from his roles, resulting in a genuine departure.
Why it matters: The study tests for brain signals linked to OV4071's proposed effect. Positive results would support moving toward a Phase 2 study.
Supportive ifOvid reports the challenge study started in the second half of 2026. Results show changes in planned brain signals or biomarkers.
Worry ifThe study does not begin by year-end 2026, or reported results show no change in the planned brain signals or biomarkers.
Why it matters: Ovid reported $169.8 million in cash and said its runway reaches 2029. New cash and spending data can test that claim.
Worry ifThe November 11 update reports at least $169.8 million in cash and marketable securities. It keeps the runway into 2029.
Less concerning ifThe November 11 update reports cash below $169.8 million and a stated runway that ends before 2029.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$217 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $672 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,736 loss on $10,000 · 27.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.